Metactive Medical Among "12 Kansas City Startups to Watch in 2019"

Metactive Medical, a Serra Capital III portfolio company, was recently featured by Startland as one of “12 Kansas City Startups to Watch in 2019.” Metactive was chosen as a top 12 company from a pool of 250 companies, and was judged on leadership, disruptiveness, traction and the likelihood of major news in 2019.

Metactive is developing novel, endovascular medical devices for the treatment of peripheral and neurovascular diseases. Metactive's first products enable precise and immediate occlusion and rapid sealing of cerebral aneurysms and other target vessel segments using an over-the-wire microcatheter platform.

Source: https://www.startlandnews.com/2019/01/kansas-city-startups-to-watch/


Metactive Medical Presents Results from Nonclinical Research Study

Metactive Medical, a Serra Capital III portfolio company, presented new nonclinical results from Metactive’s peripheral vascular research program at the Society of Interventional Radiology (SIR) Annual Scientific Meeting on July 23. The study was conducted on the treatment of peripheral arteries, and showed the effectiveness of Metactive's solution over other treatments. 

Metactive Medical is a medical device company developing innovative products for the treatment of neurovascular and peripheral vascular diseases.

Source: https://www.businesswire.com/news/home/20180723005192/en/Metactive-Presents-Results-Nonclinical-Research-Study-Treating